ICU Medical (ICUI) to Release Earnings on Tuesday

ICU Medical (NASDAQ:ICUI) will be announcing its earnings results after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of $0.84 per share for the quarter. ICU Medical has set its FY24 guidance at $4.40-5.10 EPS and its FY 2024 guidance at 4.400-5.100 EPS.Investors interested in registering for the company’s conference call can do so using this link.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Tuesday, February 27th. The medical instruments supplier reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.39. ICU Medical had a positive return on equity of 6.35% and a negative net margin of 1.31%. The firm had revenue of $587.86 million for the quarter, compared to the consensus estimate of $564.77 million. On average, analysts expect ICU Medical to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

ICU Medical Price Performance

Shares of ICUI stock opened at $99.99 on Monday. ICU Medical has a fifty-two week low of $78.28 and a fifty-two week high of $212.43. The stock’s 50-day moving average is $100.98 and its two-hundred day moving average is $97.19. The company has a quick ratio of 1.06, a current ratio of 2.53 and a debt-to-equity ratio of 0.74.

Insiders Place Their Bets

In other ICU Medical news, COO Christian B. Voigtlander sold 13,603 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $107.19, for a total transaction of $1,458,105.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director George A. Lopez sold 7,978 shares of the firm’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $101.87, for a total value of $812,718.86. Following the sale, the director now directly owns 877,343 shares of the company’s stock, valued at $89,374,931.41. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Christian B. Voigtlander sold 13,603 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $107.19, for a total value of $1,458,105.57. The disclosure for this sale can be found here. Insiders sold 24,262 shares of company stock valued at $2,545,532 over the last quarter. Insiders own 6.70% of the company’s stock.

Wall Street Analyst Weigh In

Separately, KeyCorp lifted their target price on shares of ICU Medical from $134.00 to $136.00 and gave the company an “overweight” rating in a research note on Wednesday, February 28th. One research analyst has rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $123.00.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.